Axon Short Sellers Add Positions Before Tuesday's Print

AXON heads into its November 3 earnings report with short sellers building positions at a pace that stands out from the broader defense-tech complex.

Short interest has climbed 21% over the past month to 5.4% of the free float, with roughly 4.2 million shares now on loan. The weekly build of 9.5% is the more notable move: most of that accumulation happened in the five sessions ending October 23, when short positions jumped from 3.8 million to 4.3 million shares in a single week. Borrow costs remain low at 0.57%, up about 11% on the week but still well within cheap territory. Availability is loose at 843%, meaning there are roughly eight shares available to borrow for every one currently shorted. That rules out any squeeze pressure; shorts are adding with ample capacity behind them.

The stock's own price action cuts against the bearish positioning. Axon has gained 1.8% over the past week, closing at $427.77 on Friday. That trails its closest peers badly: AVAV added 14.6% on the week, RCAT gained 15.6%, and KTOS rose 13.9%. Axon fell 2.3% on Friday alone, the one session where peers were sharply up. Options traders are not reflecting the same caution as short sellers. The put/call ratio has dropped to 0.70, more than one standard deviation below its 20-day average of 0.86 and near the 52-week low. That is the opposite of defensive positioning.

The analyst community remains broadly constructive but has been trimming numbers into the print. TD Cowen lowered its price target to $800 from $825 on October 26, keeping a Buy rating. Piper Sandler made a sharper cut on October 20, reducing its target to $561 from $732 while staying Overweight. The mean Street target of $680 still implies roughly 59% upside from Friday's close, a gap that reflects genuine disagreement about timing rather than direction. Bulls point to 30% to 35% revenue growth, a $159 billion total addressable market, net revenue retention of 125%, and accelerating international sales, which more than doubled and reached 20% of quarterly revenue last quarter. Bears focus on a free cash flow miss in the most recent quarter, adjusted FCF of negative $54 million against consensus of $180 million, a full-year FCF guide that trails consensus estimates, and antitrust attention from the FTC. The PE of roughly 44 times leaves little room for further guidance cuts.

Institutional holders have been adding steadily. BlackRock reported 10.3% of shares at end of September, up from 8.2% at its prior filing. FMR added 544,680 shares in the quarter. Westfield Capital added 427,356 shares. On the insider side, the recent activity is less meaningful for signal: CEO Patrick Smith's September sales totalling roughly 7,300 shares were executed under pre-arranged 10b5-1 plans, making them scheduled rather than discretionary. The single non-plan transaction was a tax-withholding filing by the Chief Revenue Officer in October, not an open-market sale.

Tuesday's print is therefore less a test of whether Axon is growing and more a test of whether the company can close the gap between its revenue trajectory and its free cash flow delivery, given that the Street's bear case rests almost entirely on that disconnect rather than on the core business.